Login to Your Account



Pharma: Clinic Roundup


Tuesday, September 10, 2013
Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported Phase III data at the European Respiratory Society meeting in Barcelona, Spain, showing that once-daily olodaterol Respimat maintained lung function improvements in addition to usual care over 24 hours and demonstrated rapid onset of action within five minutes after the first dose in patients with chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription